PT - JOURNAL ARTICLE AU - Liliana Raposo AU - Raquel Barros AU - Ana Sofia Oliveira AU - João Valença AU - Cristina Bárbara TI - Bronchodilation test: Salbutamol or Ipratropium Bromide? AID - 10.1183/13993003.congress-2020.2648 DP - 2020 Sep 07 TA - European Respiratory Journal PG - 2648 VI - 56 IP - suppl 64 4099 - http://erj.ersjournals.com/content/56/suppl_64/2648.short 4100 - http://erj.ersjournals.com/content/56/suppl_64/2648.full SO - Eur Respir J2020 Sep 07; 56 AB - Background: The evaluation of the response to bronchodilator in pulmonary obstructive pathologies is crucial for the diagnosis and clinical follow-up of the individuals. β-adrenergic agonists and anticholinergics are the most frequently used.Objectives: To characterize the response of bronchodilation according to the drug used; to identify differences in response of bronchodilation according to the pathology; to determine the agreement of the response to bronchodilator considering Salbutamol (Sb) or Ipratropium Bromide (IB).Methodology: Cross-sectional study. 141 individuals with airway obstruction were included (39 asthmatics and 102 COPD) and underwent two spirometry tests with an 8-day interval. In half of the sample Sb was used on the first visit and IB on the second, and in the other half the order was reversed. An increase of ≥12% and ≥200mL in FVC and/or FEV1 was considered a positive bronchodilation.Results: The analysis of the means of study variables didn’t revealed significant differences (p>0.05) between Sb and IB. The average of the differences between the parameters was 60mL and 1.92% for FVC and 40mL and 1.53% for FEV1. Bronchodilation was positive in 17.7% of the sample (Sb), 19.1% (IB) and 26.2% (Sb+IB). In COPD group, a positive response was observed in 15.7% (Sb), 18.6% (IB) and 30.4% (Sb+IB) and in the asthma group 23.1% (Sb), 20.6% (IB) and 15.4% (Sb+IB). The Kappa agreement coefficient revealed that the response to bronchodilator is different depending of the used drug (Kappa=0.254; p=0.003).Conclusion: The characterization of the response to the bronchodilator showed to be different according to the drug used, and it was found that asthmatic individuals respond mostly to Sb and COPD to the IB.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2648.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).